Abstract:Oxidative stress and cytotoxic damage induced by amyloid beta (Aβ) have been considered pivotal in the pathogenesis of Alzheimer’s disease (AD) and may represent a target for treatment. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway elicits a survival signal to protect against multiple injuries, and the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), a downstream target of the PI3K/Akt pathway, can bind to HO-1. Resveratrol, a natural polyphenol derived from grapes, has been widely reported to have diverse antioxidative effects against AD, but the mechanisms have not been fully elucidated. The present study aims to investigate the effects of resveratrol on Aβ1–42-induced cytotoxicity in PC12 cells and to explore the potential mechanisms of these effects. PC12 cells were cultured and treated with Aβ1–42. Oxidative stress was assessed by measuring malondialdehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD) levels. After treating with resveratrol at different concentrations (0, 10, 20, 40 μM) and for different durations (24, 48, 72 h), the generation of MDA, GSH, and SOD were detected; cell viability was assessed by MTT assay. The production of reactive oxygen species (ROS) was determined using an ROS Assay Kit. Western blotting was used to detect the protein expression. Our studies showed that pretreatment with resveratrol could reduce Aβ1–42-induced oxidative stress in PC12 cells by inhibiting the generation of MDA and ROS and increasing the production of SOD and GSH. Resveratrol markedly attenuated the Aβ1–42-induced loss in cell viability in PC12 cells in both a dose- and time-dependent manner. More importantly, resveratrol stimulated the activation of HO-1, Nrf2, PI3K, and phosphorylated Akt. Notably, the neuroprotective effects of resveratrol were eliminated by the HO-1 inhibitor zinc protoporphyrin IX (ZnPP), Nrf2 small interfering RNA (siRNA), and the PI3K/Akt inhibitor LY294002. Taken together, the findings suggest that the cytoprotection of resveratrol against the cytotoxicity induced by Aβ1–42 in PC12 cells is through the upregulation of HO-1 expression via the activation of the PI3K/AKT/Nrf2 intracellular signaling pathway, which might provide novel insights for understanding the mechanism of the neuroprotective effect of resveratrol as an anti-AD drug.

Resveratrol Attenuates Aβ-Induced Early Hippocampal Neuron Excitability Impairment via Recovery of Function of Potassium Channels

Resveratrol Attenuates the Cytotoxicity Induced by Amyloid-β1–42 in PC12 Cells by Upregulating Heme Oxygenase-1 via the PI3K/Akt/Nrf2 Pathway

Resveratrol Inhibits Β-Amyloid-induced Neuronal Apoptosis Through Regulation of SIRT1-ROCK1 Signaling Pathway.

Resveratrol Attenuates Oxidative Damage Through Activating Mitophagy in an in Vitro Model of Alzheimer's Disease.

Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by β-amyloid through activation of SIRT1/Akt1 pathway.

Resveratrol Attenuates Β-Amyloid-induced Oxidative Stress in Astrocytes.

Astrocytic AT1R deficiency ameliorates Aβ-induced cognitive deficits and synaptotoxicity through β-arrestin2 signaling

Resveratrol Inhibits Β-Amyloid-induced Neuronal Apoptosis Via Regulation of P53 Acetylation in PC12 Cells.

Autophagy-ERK1/2-Involved Disinhibition of Hippocampal Neurons Contributes to the Pre-Synaptic Toxicity Induced by Aβ42 Exposure.

Resveratrol inhibits oligomeric Aβ‑induced microglial activation via NADPH oxidase

Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation.

Resveratrol Protects Against Neurotoxicity Induced by Kainic Acid

Stimulation of autophagy prevents amyloid-β peptide-induced neuritic degeneration in PC12 cells.

Research Progress on Alzheimer's Disease and Resveratrol

Genistein Inhibits Aβ 25–35 -Induced Neuronal Death with Changes in the Electrophysiological Properties of Voltage-Gated Sodium and Potassium Channels

The resveratrol trimer miyabenol C inhibits β-secretase activity and β-amyloid generation.

Resveratrol As A Therapeutic Agent for Alzheimer'S Disease

Resveratrol as a therapeutic agent for Alzheimer's disease.

Neuroprotective Effect of Trans -Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

Resveratrol Attenuates the Disruption of Lipid Metabolism Observed in APP/PS1 Mouse Brains and Cultured Primary Neurons Exposed to Aβ

Involvement of Intracellular and Mitochondrial Aβ in the Ameliorative Effects of Huperzine A Against Oligomeric Aβ42-Induced Injury in Primary Rat Neurons